| GHRPs and GHSs |
WADA-ISO/IEC 17025 |
selectivity, matrix effects, recovery,
linearity, intra- and
interassay precisions, and LOD |
linearity (r = 0.9984–1) |
| |
|
|
matrix effect
= 50.0%–141.2% |
| |
|
|
recovery = 10.4%–100.8% |
| |
|
|
intra- and interday precision
(CV < 20% and CV < 25%, respectively) |
| |
|
|
LOD (for screening 0.05–0.5 ng/mL; for confirmation 0.05–1 ng/mL)97
|
| mixture of peptides used in doping |
ISO-17025 |
selectivity,
linearity, precision, accuracy, LOQ, and LOD |
linearity (r > 0.999) |
| |
|
|
LOD (μg/mL): GHRP-2 = 0.05; GHRP-6 = 0.05; leuprolide = 0.1; buserelin = 0.1; sermorelin = 2.5 |
| |
|
|
LOQ (μg/mL):
GHRP-2 = 5; GHRP-6 = 5; Ipamorelin = 5; sermorelin = 40101
|
| mixture of peptides
used in doping |
WADA |
selectivity, matrix
effects, recovery, linearity, intra- and
interassay precisions, carry over, and LOD |
linearity (r = 0.9862–0.9999) |
| |
|
|
matrix
effect = 33%–156% |
| |
|
|
LOD (ng/mL): 0.5–20 |
| |
|
|
carryover (after 100 ng/mL) = 0%–9.9% |
| |
|
|
recovery (at 20 ng/mL) = 8.0%–69.6%90
|
| mixture of peptides used in doping |
WADA-ISO/IEC 17025 |
selectivity, recovery, matrix
effect, precision, sensitivity
(limit of detection), cross contamination, carryover, robustness,
and stability |
LOD (ng/mL): 0.1–1 |
| |
|
|
matrix effect = 12%–80% |
| |
|
|
recovery
SPE = 17%–95%55
|
| GHRHs |
N.R. |
specificity, linearity, recovery, LLOD, imprecision, and ion
suppression/enhancement effects |
lower limit of detection
(LLOD) (pg/mL) = sermorelin < 50; CJC-1295 |
| |
|
|
recovery
= sermorelin 23%; CJC-1295 19%102
|
| GHRP-6 |
FDA |
sensitivity (LOQ, carry over), calibration range and response,
accuracy and precision, and sample stability |
lower limit
of quantification (LLOQ) = 5 ng/mL |
| |
|
|
linearity 5–50 ng/mL (r = 0.988)103
|
| IGF-1 |
WADA-ISO/IEC 17025 |
linearity, selectivity, carry
over, LOD, LOQ, intra and interday
precision, recovery, and accuracy |
linearity (r = 0.9994) |
| |
|
|
LOD = 15 ng/mL |
| |
|
|
LOQ = 20 ng/mL |
| |
|
|
recovery > 95% |
| |
|
|
carryover < 0.03%98
|
| leuprolide |
ICH |
specificity, linearity, LLOQ, selectivity, precision, accuracy,
extraction recovery, matrix effect, and stability |
linear
dynamic range = 0.0500–40 ng/mL |
| |
|
|
lower limit of quantification (LLOQ) = 0.0500 ng/mL100
|
| desmopressin and vasopressin |
N.R. |
specificity, recovery, linearity, precision (intra/inter-day),
LOD, LOQ, ion suppression, robustness, accuracy, and stability |
linearity (r > 0.99) |
| |
|
|
LOD = 20 pg/mL |
| |
|
|
LOQ = 50 pg/mL |
| |
|
|
recovery = 81%–103%104
|
